AI assistant
PULSE BIOSCIENCES, INC. — Director's Dealing 2025
Oct 8, 2025
32093_dirs_2025-10-07_d44f9ed9-a9ba-4738-9c08-48a5a86fe6aa.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PULSE BIOSCIENCES, INC. (PLSE)
CIK: 0001625101
Period of Report: 2025-10-02
Reporting Person: Danahy Kevin Patrick (Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-10-02 | Common Stock | M | 4600 | $1.53 | Acquired | 47898 | Direct |
| 2025-10-02 | Common Stock | S | 4600 | $18.53 | Disposed | 43298 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-10-02 | Stock Option (right to buy) | $1.53 | M | 4600 | Disposed | 2032-09-23 | Common Stock (4600) | Direct |
Footnotes
F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025.
F2: The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $18.48 to $18.65 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range.
F3: Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022.